Stockscreener 앱 받기
24.69
0.60%
-0.15
전일 마감가:
$24.84
열려 있는:
$24.9
하루 거래량:
937.55K
Relative Volume:
0.78
시가총액:
$3.02B
수익:
$460.48M
순이익/손실:
$142.80M
주가수익비율:
20.92
EPS:
1.18
순현금흐름:
$221.79M
1주 성능:
+1.90%
1개월 성능:
+13.99%
6개월 성능:
+26.23%
1년 성능:
+54.89%
1일 변동 폭
$24.25
$24.98
1주일 범위
$24.25
$26.16
52주 변동 폭
$14.47
$26.16
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
24.69 | 3.02B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’ - Insider Monkey
With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business - Yahoo Finance
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) large institutional owners must be happy as stock continues to impress, up 18% over the past week - Simply Wall St
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day - GlobeNewswire Inc.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Yahoo Finance
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Bank of New York Mellon Corp Raises Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Proficio Capital Partners LLC Makes New $339,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts - Seeking Alpha
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Gary Ingenito Sells 44,904 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - Defense World
Where are the Opportunities in (CPRX) - Stock Traders Daily
Catalyst Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Executive VP & Chief Commercial Officer Jeffrey Del Carmen Sold A Bunch Of Shares In Catalyst Pharmaceuticals - Simply Wall St
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock - Investing.com India
Carmen Del Sells 30,423 Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus.com
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock - Investing.com
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Executives Conduct Major Stock Transactions - TradingView
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Robust Earnings Are Conservative - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference - GlobeNewswire
When and Where to Hear Catalyst Pharmaceuticals' Future Plans: CEO Set for Major Healthcare Conference - StockTitan
Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $32.00 at Robert W. Baird - Defense World
Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges - Seeking Alpha
Catalyst Pharmaceuticals’ (CPRX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to Strong-Buy at StockNews.com - Defense World
Sanctuary Advisors LLC Has $1.24 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates - MSN
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highli - GuruFocus.com
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap UpHere's What Happened - MarketBeat
Catalyst Pharmaceuticals' (CPRX) "Overweight" Rating Reaffirmed at Stephens - MarketBeat
Oppenheimer Adjusts Price Target on Catalyst Pharmaceuticals to $32 From $31, Maintains Outperform Rating - Marketscreener.com
Ieq Capital LLC Invests $313,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Principal Financial Group Inc. Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Earnings call transcript: Catalyst Pharmaceuticals Q4 2024 beats expectations By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Catalyst Pharmaceuticals Reports Record 2024 Financial Results - TipRanks
Catalyst Pharmaceuticals Reports Strong Growth Amid Challenges - TipRanks
Catalyst Pharmaceuticals (NASDAQ:CPRX) Announces Quarterly Earnings Results - MarketBeat
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today - MSN
Catalyst Pharmaceuticals Inc (CPRX) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Catalyst Pharmaceuticals Inc 주식 (CPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 05 '25 |
Option Exercise |
2.24 |
44,904 |
100,585 |
113,777 |
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 06 '25 |
Sale |
21.67 |
180,096 |
3,902,680 |
68,873 |
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 05 '25 |
Sale |
22.09 |
44,904 |
991,929 |
68,873 |
0.39%
0.34%
자본화:
|
볼륨(24시간):